$SNDX
Syndax Pharmaceuticals Inc
Runway:21 mo
NasdaqMarket cap: —CIK 0001395937
Upcoming catalysts
0 surfacedNo catalysts surfaced for SNDX yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07211958 | Revumenib | Phase 3 | Recruiting | 2029-06-01 |
| NCT04065399 | Revumenib | Phase 2 | Recruiting | 2027-12-15 |
| NCT06226571 | SNDX-5613 | Phase 1 | Recruiting | 2027-02-01 |
| NCT06132256 | Axatilimab | Phase 2 | Active Not Recruiting | 2026-09-01 |
| NCT05731947 | Revumenib | Phase 2 | Completed | 2025-06-30 |
| NCT05406817 | Revumenib | Phase 1 | Completed | 2024-11-18 |
| NCT05326516 | Revumenib | Phase 1 | Completed | 2024-07-29 |
| NCT04710576 | Axatilimab | Phase 2 | Active Not Recruiting | 2023-04-07 |
| NCT02437136 | Entinostat | Phase 2 | Completed | 2022-09-29 |
| NCT03604692 | Axatilimab | Phase 2 | Completed | 2022-08-12 |
| NCT02708680 | Entinostat | Phase 2 | Completed | 2021-03-31 |
| NCT03238027 | Axatilimab | Phase 1 | Completed | 2020-11-20 |
| NCT04415073 | SNDX-6352 | Phase 2 | Terminated | 2020-07-13 |
| NCT02909452 | Entinostat | Phase 1 | Completed | 2019-07-17 |
| NCT02915523 | Entinostat | Phase 2 | Completed | 2019-02-21 |
| NCT02820961 | Entinostat | Phase 1 | Completed | 2018-09-10 |
| NCT03192111 | Entinostat | Phase 1 | Completed | 2017-11-23 |
| NCT03187015 | Entinostat | Phase 1 | Completed | 2017-06-04 |
| NCT02922946 | Entinostat | Phase 1 | Completed | 2017-05-20 |
| NCT02922933 | Entinostat | Phase 1 | Completed | 2017-04-19 |